Kyriat Weizmann, Israel (PRWEB) June 05, 2013
Hemostemix, Ltd. (“Hemostemix”, the “Company”) announced today the issuance of a Notice of Allowance from the United States Patent and Trademark Office for a patent entitled “A Composition Comprising A Progenitor/Precursor Cell Population”.
The patent pertains to a population of cultured cells which meet certain criteria and constitute the foundation of the Company’s angiogenic (blood vessel growing) technology. The product developed on the basis of this technological platform will be used in a Phase 2 clinical trial for critical limb ischemia. The trial protocol was recently cleared by Health Canada and the trial is expected to commence later this year.
This patent is part of a broad technology platform now protected by 38 patents issued in major markets, such as the US, EU, Japan and China. The company continues to aggressively file and prosecute patents around all aspects of its technology as an important foundation for its global commercialization plans.
“The cell population which is the subject of this patent,” stated Hemostemix’ President, Dr. Valentin Fulga, “is an important pillar of our technology. This cell population is generated from a core population of cells we named Synergetic Cell Population (“SCP”), which is isolated from a simple blood collection. We believe the SCP not only has the potential to differentiate into blood vessels, but can also be transformed, through proprietary cell-culturing techniques, into other cell types, such as cardiomyocyte-like cells and neural cells.”
About Hemostemix Ltd
Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park
Copyright©2012 Vocus, Inc.
All rights reserved